Head to head
LivaNova vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: LIVN · ABT
LIVN
LivaNova
90.73-1.46%
1-year price shape — +70% over the period
Quant Rating C · 93/100
vs
ABT
Abbott Laboratories
103.00-0.84%
1-year price shape — -15% over the period
Quant Rating D · 20/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| LIVN | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 90.73 | 103.00 |
| Change today | -1.46% | -0.84% |
| 1-year return | +69.8% | -15.4% |
| Market cap | $5.00B | $178.39B |
| 52-week range | 56.44 – 99.38 | 80.89 – 126.70 |
| Valuation | ||
| P/E (TTM) | 26.00 | 38.29 |
| P/E percentile, own 5-yr range | 75th | 99th |
| P/B | 3.64 | 3.50 |
| Dividend yield | 0.00% | 2.41% |
| Profitability & growth | ||
| EPS (TTM) | -4.45 | 3.72 |
| Net profit (TTM) | $-245.14M | $6.44B |
| Revenue (TTM) | $1.51B | $48.23B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +9.9% | +14.5% |
| Gross margin | 67.8% | 56.9% |
| Operating margin | 10.7% | 13.8% |
| Net margin | 13.0% | 9.7% |
| Free cash flow (TTM) | $129.02M | $6.76B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 117.4% | 81.2% |
| Insider activity (12mo) | 29 buy / 20 sell | 36 buy / 12 sell |
| Short interest (% of float) | 11.5% | 1.1% |
| Analyst consensus | 100% buy (6) | 93% buy / 7% hold (15) |
| Analyst price target | $111 (+23%) | $122 (+18%) |
| StockVane view | ||
| StockVane Quant Rating | C (93) | D (20) |
| Company | ||
| Employees | 3,300 | 115,000 |
| Founded | 1987 | 1900 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.